ClinicalTrials.gg
RecruitingNCT06075173Updated Oct 10, 2023

Resting Full-cycle Ratio in Side Branch

An observational study in Coronary Artery Disease, sponsored by Sejong General Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Sejong General Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2020; still recruiting 6 years 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
286
Ages
20 Years to 90 Years
Sex
All
01

Study summary

The goal of this observational study is to evaluate diagnostic performance of resting full-cycle rate (RFR) in side branch lesion.

We aims to evaluate whether the diagnostic performance of RFR in the side branch lesion is non-inferior compared to that in the main vessel lesion RFR and FFR measurements will be performed to define functional significance in patients with side branch lesion with or without main vessel lesion

Read the detailed description

The presence of myocardial ischemia is the most important prognostic indicator in patients with coronary artery disease. Pressure-based functional assessment has been recommended to assess the presence of myocardial ischemia due to low accuracy of image-based assessment in intermediate coronary artery disease. Selective revascularization for only ischemia-producing lesion with fractinal flow reserve(FFR) guidance proved to decrease adverse cardiac events and avoid unnecessary coronary stenting, compared to angiography-guided revascularization. Therefore, Current guidelines strongly recommend FFR measurement for the assessment of the functional severity of moderate stenosis of a culprit lesion in stable coronary artery disease, and non-culprit lesion in acute coronary syndrome. However, it's clinical adaption in a real world was still very low, because of the need of pressure wire and hyperemic agent. Instantaneous flow ratio (iFR), which the ratio of distal coronary artery pressure to aortic pressure during wave-free period at rest, had a high diagnostic accuracy to define functional significance without need of adenosine. According to two large randomized trials, iFR-guided coronary revascularization proved to be non-inferior to FFR-guided revascularization with respect to one-year risk of major adverse cardiac events. Recently, new adenosine-free index, called as a resting full-cycle ratio (RFR), which is completely independent of the ECG and irrespective of systole or diastole has been validated to detect myocardial ischemia. RFR is not limited by sensitive land marking of components of the pressure waveform unlike iFR, and is diagnostically equivalent to iFR.

This novel physiologic index without need of adenosine have a potential to widely spread of functional assessment for coronary artery stenosis in daily clinical practice, and simplify procedure in complex coronary artery disease. Therefore, we sought to investigate diagnostic performance of this novel physiologic index to define myocardial ischemia in coronary bifurcation lesion, which is one of complex lesion subset.

02

Conditions studied

  • Coronary Artery Disease

Keywords

  • bifurcation lesion
  • physiologic assessment
03

In context

Coronary Artery Disease

4,857 studies on the registry are indexed under Coronary Artery Disease; 890 are open to participants now.

This study's planned enrollment of 286 is below the median of 320 across 1,687 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Sejong General Hospital is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with side branch lesion, who need functional evaluation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with side branch lesion, who need functional evaluation

Exclusion criteria

Exclusion Criteria:

  • Severe LV systolic dysfunction ( \<30%)
  • Culprit vessel in acute coronary syndrome
  • Donor vessel to supply chronic total occlusion lesion of non-target vessel
  • Symptomatic valvular heart disease or cardiomyopathy
  • Too much overlapping or severe tortuosity to disrupt quantitative coronary analysis
  • Previous bypass surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
286 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Interventions

  • Diagnostic testResting full-cycle ration (RFR) measurments

    RFR and FFR measurements in main vessel and side branch lesions

    Also known as: fractional flow ratio (FFR) measurments

06

What researchers measure

Primary outcomes

  1. diagnostic sensitivity of RFR in side branch lesions

    diagnostic sensitivity of RFR to predict FFR \< 0.80

    Time frame: during index coronary angiography

Secondary outcomes

  1. Specificity, positive predictability, negative predictability, diagnostic accuracy, area under the curve (AUC) value in side branch

    diagnostic performances of RFR to predict FFR \< 0.80

    Time frame: during index coronary angiography

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06075173
Lead sponsor
Sejong General Hospital
Collaborators
Soon Chun Hyang University, Keimyung University Dongsan Medical Center, Hanyang University Seoul Hospital
Responsible party
Hyun Jong Lee (MD, PhD, Sejong General Hospital) — Principal investigator
First posted
Oct 10, 2023
Start date
Jan 8, 2020
Primary completion
Jun 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Oct 10, 2023

Study contacts

Hyun-Jong Lee, MD, PhD
Contact
untouchables00@hanmail.net
82-10-6217-9315
Su Jung Lee, RN
Contact
bjwwoki0827@daum.net
82-32-340-1812

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion